Ultragenyx Resolves DOJOLVI Patent Dispute, Securing Exclusivity Through 2033
RARE sits 49% above its 52-week low of $18.29.
Summary
Ultragenyx settled patent litigation with Esjay Pharma, granting a royalty-free license for generic DOJOLVI starting in 2033. The deal eliminates one generic threat but leaves other ANDA challenges unresolved.
Key Events · Legal and Risk Events · RARE
-
DOJOLVI Patent Settlement
Ultragenyx and Baylor Research Institute settled with Esjay Pharma, granting a non-exclusive, royalty-free license for generic DOJOLVI starting January 1, 2033 (or July 1, 2033 with pediatric exclusivity).
-
Generic Entry Delayed
The settlement pushes the earliest generic competition for DOJOLVI to 2033, preserving market exclusivity for approximately 6.5 years.
-
Pending ANDA Litigation
Similar patent litigation against other ANDA filers remains pending in New Jersey federal court, meaning additional settlements or adverse rulings could still shorten exclusivity.
-
Strategic Trade-Off
The royalty-free license suggests Ultragenyx prioritized removing litigation uncertainty over potential licensing income, a reasonable move given the company's focus on upcoming gene therapy PDUFA dates (DTX401 on Aug 23, UX111 on Sep 19).
Analysis · RARE · Life Sciences
By removing a near-term overhang on DOJOLVI—a key revenue driver—the settlement delays generic competition until at least 2033. Still, other ANDA challenges remain pending, so litigation risk is not fully resolved. The royalty-free license suggests the company prioritized certainty over potential licensing revenue, a pragmatic trade-off given the upcoming PDUFA dates for its gene therapy pipeline.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.7% of the 1731 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RARE was trading at $27.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $18.29 to $39.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.